V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20194172 | 20178793 | 1.84 | 56.8 | null | 2018-01-09 | 2018-01-31 | CISPLATIN + TEYSUNO | 02 | N | CISPLATIN + RT | 100352389 |
| 20194533 | 20178794 | 1.75 | null | null | 2018-01-16 | 2018-01-16 | FCR Oral - Cycle 2 onwards | N | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100062470 |
| 20197298 | 20178795 | 1.8 | 71 | null | 2021-03-31 | 2021-03-31 | MITOMYCIN | 02 | null | PALBOCICLIB | 101227674 |
| 20198126 | 20178798 | 1.65 | 97 | Palliative (P) | 2021-02-15 | 2021-02-15 | CARBOPLATIN + RT | 02 | null | FOCUS4 TRIAL | 100341536 |
| 20198192 | 20178799 | 1.92 | 96.9 | Palliative (P) | 2019-11-01 | 2019-11-03 | IBRUTINIB | 02 | null | COSMIC TRIAL | 100980667 |
| 20199648 | 20178800 | 1.57 | 81.3 | Palliative (P) | 2021-03-12 | 2021-03-12 | Fulvestrant + Palbociclib | 02 | null | CAP + RT | 100122884 |
| 20199729 | 20178801 | 1.62 | 91 | Palliative (P) | 2020-08-11 | 2020-08-12 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | N | BORTEZOMIB + THALIDOMIDE | 100995507 |
| 20200823 | 20178802 | 1.71 | 92.2 | Palliative (P) | 2014-01-16 | 2018-11-29 | Procarbazine | null | N | DASATINIB | 100337471 |
| 20201314 | 20178804 | 1.86 | 51.1 | Curative (C) | 2018-05-02 | 2018-11-06 | Cabazitaxel | 02 | N | ECF | 101256435 |
| 20203204 | 20178805 | 1.79 | 69.7 | Palliative (P) | 2021-02-12 | 2021-02-21 | CABOZANTINIB | 02 | N | CARBOPLATIN + VINORELBINE | 101602500 |
| 20203627 | 20178806 | 1.81 | 63.7 | Palliative (P) | 2022-05-21 | 2022-05-27 | SCOPE 2 TRIAL | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101042890 |
| 20204423 | 20178808 | 1.51 | 68 | Palliative (P) | 2022-01-06 | 2022-01-06 | ECarboX | 02 | N | ACELARATE TRIAL | 100383333 |
| 20206048 | 20178812 | 1.77 | 65.8 | Curative (C) | 2019-12-29 | 2019-12-29 | CISPLATIN + FLUOROURACIL + Trastuzumab | 02 | null | PHITT D2 CARBOPLATIN / ETOPOSIDE | 101257517 |
| 20206119 | 20178813 | 1.8 | 60 | null | 2018-03-01 | 2018-03-01 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100637538 |
| 20206443 | 20178814 | 1.74 | 80.2 | null | 2018-12-26 | 2019-01-05 | ARISTOTLE TRIAL | 02 | N | CARBOPLATIN + RALTITREXED | 101450822 |
| 20206480 | 20178815 | 1.6 | 111 | Palliative (P) | null | 2018-08-28 | FOCUS4 TRIAL | 02 | N | TOPOTECAN | 100364677 |
| 20206530 | 20178816 | 1.55 | 73.2 | Curative (C) | 2019-08-14 | 2019-08-18 | EEF or EOF | 02 | null | BEVACIZUMAB + FLUOROURACIL + OXALIPLATIN | 101395576 |
| 20206644 | 20178817 | 1.65 | 60.5 | Palliative (P) | 2020-01-06 | 2020-01-06 | BENDAMUSTINE | 02 | N | RITUXIMAB | 101417379 |
| 20207941 | 20178818 | null | null | null | 2020-01-27 | 2020-07-16 | Pertuzumab | 02 | N | BORTEZOMIB + THALIDOMIDE | 100556932 |
| 20208403 | 20178819 | 1.82 | 57.2 | null | 2022-04-03 | 2022-05-02 | null | 02 | null | FLUOROURACIL + INTERFERON ALFA | 101228832 |
| 20208450 | 20178820 | 1.69 | 69.9 | Palliative (P) | 2020-11-24 | 2020-12-21 | Docetaxel+Gemcitabine (no prior RT) | 02 | N | CISPLATIN + IFOSFAMIDE + MITOMYCIN | 101828578 |
| 20211578 | 20178823 | 1.58 | 59 | Palliative (P) | 2021-09-01 | 2021-09-11 | Cisplatin + Fluorouracil + RT 5day | 02 | N | PLATO TRIAL | 100774675 |
| 20212294 | 20178824 | 1.79 | 68.6 | Curative (C) | 2019-09-22 | 2019-12-25 | EOF | 02 | null | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100988487 |
| 20213191 | 20178826 | 1.58 | 115.9 | 03 | 2021-11-15 | 2022-01-21 | FCiSt | 02 | N | TEMOZOLOMIDE | 101484197 |
| 20214103 | 20178827 | 1.53 | 95.55 | Palliative (P) | 2017-06-28 | 2017-06-28 | SCOPE 1 TRIAL | 02 | N | DABRAFENIB + TRAMETINIB | 100473129 |
| 20214585 | 20178828 | 1.73 | 47 | null | 2018-08-14 | 2018-08-19 | ECarboX | 02 | N | INTERAACT TRIAL | 100678103 |
| 20215650 | 20178831 | 1.61 | 102 | 03 | 2020-09-05 | 2020-09-05 | Pazopanib | 02 | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100892795 |
| 20215936 | 20178832 | 1.8 | 62.9 | null | 2019-12-23 | 2019-12-29 | CT7001 | 02 | null | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 101630201 |
| 20216542 | 20178833 | 1.69 | 86.6 | null | 2021-09-08 | 2021-09-18 | null | 02 | null | INTERAACT TRIAL | 100867680 |
| 20217411 | 20178836 | 1.73 | 88.2 | Curative (C) | 2021-08-14 | 2021-08-18 | Bevacizumab + CAPECITABINE + OXALIPLATIN | 02 | N | CARBOPLATIN + VINORELBINE | 101264157 |
| 20217473 | 20178837 | 1.83 | 98.4 | null | 2021-09-25 | 2021-11-01 | Derazantinib | 02 | null | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 101055865 |
| 20217550 | 20178838 | 0 | 115.9 | Palliative (P) | 2019-12-26 | 2019-12-28 | Bortezomib + CYCLOPHOSPHAMIDE | 2 | null | CABAZITAXEL | 101585541 |
| 20218161 | 20178839 | 1.8 | 81 | Palliative (P) | 2019-10-24 | 2019-10-25 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | null | CABAZITAXEL | 100382991 |
| 20220087 | 20178840 | 1.57 | 92.5 | Adjuvant (A) | 2018-10-12 | 2018-11-23 | Capecitabine + Streptozocin | null | N | BORTEZOMIB + RITUXIMAB | 100619517 |
| 20224829 | 20178842 | 1.86 | 18.9 | Palliative (P) | 2019-09-03 | 2019-09-10 | Cabazitaxel | 2 | N | ACTICCA-1 TRIAL | 100465200 |
| 20018993 | 20178844 | 1.78 | 68 | null | 2021-12-23 | 2022-02-09 | Bendamustine+Rituximab(Sub Courses) | 02 | null | CARBOPLATIN + PEMETREXED | 101406014 |
| 20021080 | 20178845 | 1.69 | 87 | null | 2020-03-22 | 2020-03-23 | Rituximab | N | N | CETUXIMAB + FLUOROURACIL | 100564750 |
| 20033541 | 20178847 | 1.69 | 93.4 | Curative (C) | 2017-05-05 | 2017-09-08 | AML 19 TRIAL | 02 | N | CISPLATIN + FLUOROURACIL + RT | 101695090 |
| 20035688 | 20178848 | 1.77 | 112 | Curative (C) | 2018-12-18 | 2019-01-12 | Doxorubicin 20mg/m2 7 day | 02 | N | IPILIMUMAB | 100982369 |
| 20039998 | 20178849 | 1.87 | 62 | null | 2020-04-30 | 2020-07-08 | Docetaxel + nintedanib | 02 | N | IRINOTECAN + PANITUMUMAB + MDG | 101839329 |
| 20046134 | 20178850 | 1.54 | 98.2 | Curative (C) | 2018-09-05 | 2018-10-07 | CAV | 01 | N | IRINOTECAN + MDG + PANITUMUMAB | 100443890 |
| 20049933 | 20178851 | 1.52 | 87 | Palliative (P) | 2021-04-24 | 2021-12-24 | TEMOZOLOMIDE | 02 | null | IBRUTINIB | 100460285 |
| 20051858 | 20178852 | 1.74 | 91.4 | Palliative (P) | 2017-10-24 | 2017-11-08 | ACTICCA-1 Trial | Y | N | ARISTOTLE TRIAL | 101811196 |
| 20051949 | 20178853 | 1.8 | 66.3 | Curative (C) | 2021-11-03 | 2022-02-07 | ECarboX | 02 | null | CARBOPLATIN + PEMETREXED | 100930921 |
| 20065293 | 20178855 | 1.86 | 84.9 | Palliative (P) | 2020-03-25 | 2020-03-25 | CISPLATIN + FLUOROURACIL + RT | 01 | null | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 100738854 |
| 20112612 | 20178857 | 1.65 | 59.6 | Palliative (P) | 2020-01-19 | 2020-01-22 | Fluorouracil + Folinic + RT Bossett | 02 | Y | INTERAACT TRIAL | 101479073 |
| 20112952 | 20178858 | 1.69 | 55.7 | Palliative (P) | 2018-05-26 | 2018-07-08 | PERTUZUMAB + TRASTUZUMAB | 02 | N | CAPECITABINE + CETUXIMAB + OXALIPATIN | 101726390 |
| 20199357 | 20178860 | 1.8 | 66.85 | Palliative (P) | 2019-11-26 | 2019-11-27 | null | 02 | null | OSIMERTINIB | 100441603 |
| 20205619 | 20178861 | 1.75 | 68 | null | 2019-08-29 | 2019-09-19 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | null | ARISTOTLE TRIAL | 101747743 |
| 20225316 | 20178862 | 1.58 | 67.8 | Curative (C) | 2018-05-21 | 2018-11-25 | Encorafenib | 01 | N | EC | 101453265 |